Literature DB >> 9074898

Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily.

B Nia1, J M Vergnaud.   

Abstract

The comparative pharmacokinetics of Aspegic, the lysine salt of acetylsalicylic acid, administered in multi doses either through i.v. or i.m. route was studied. 1 g of drug was injected each time with a frequency of 3 times a day. The pharmacokinetic parameters were determined using the experimental data in the literature. From these results, three categories of patients were considered, depending on their response to the drug. A numerical model was established in order to evaluate the following results: the drug level in the blood compartment obtained with the i.v. or i.m. administration, as well as the area under the curve for the first day and the third day when the so-called stationary state was obtained. Approximately similar values for AUC were obtained for each route of administration, for a given category of patients. The effect of the inter-variability of the patients characterised by their response to the drug was found to be of prime importance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9074898     DOI: 10.1007/BF03189735

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Aspirin, blood loss, and transfusion.

Authors:  W A Gay
Journal:  Ann Thorac Surg       Date:  1990-09       Impact factor: 4.330

2.  Prolongation of bleeding time by aspirin: a dual mechanism?

Authors:  G de Gaetano; C Cerletti
Journal:  Thromb Res       Date:  1988-06-15       Impact factor: 3.944

3.  The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.

Authors:  C Catchpole; J M Andrews; J Woodcock; R Wise
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

4.  Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily.

Authors:  A Shah; J Lettieri; L Kaiser; R Echols; A H Heller
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

5.  Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy.

Authors:  J M Pappas; J C Westengard; B S Bull
Journal:  Arch Pathol Lab Med       Date:  1994-08       Impact factor: 5.534

6.  [Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in the treatment of a migraine attack. Randomized double-blind study using a placebo].

Authors:  P Henry; O Hiesse-Provost; A Dillenschneider; H Ganry; J Insuasty
Journal:  Presse Med       Date:  1995-02-04       Impact factor: 1.228

7.  Aspirin: dose and indications in modern stroke prevention.

Authors:  J van Gijn
Journal:  Neurol Clin       Date:  1992-02       Impact factor: 3.806

8.  Should all patients with risk factors for ischemic heart disease receive aspirin?

Authors:  J T Willerson; S D Mueller; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1992

9.  High incidence of left atrial thrombus detected by transoesophageal echocardiography in heart transplant recipients.

Authors:  G Derumeaux; D Mouton-Schleifer; R Soyer; N Saoudi; A Cribier; B Letac
Journal:  Eur Heart J       Date:  1995-01       Impact factor: 29.983

10.  Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced functional impairment model in the rat.

Authors:  G Castañeda-Hernández; M S Castillo-Méndez; F J López-Muñoz; V Granados-Soto; F J Flores-Murrieta
Journal:  Can J Physiol Pharmacol       Date:  1994-10       Impact factor: 2.273

View more
  1 in total

1.  Comparative pharmacokinetics of salicylate in camels, sheep and goats.

Authors:  B H Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.